quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:07·8d
SECFiling
Akari Therapeutics plc logo

SEC Form EFFECT filed by Akari Therapeutics plc

AKTX· Akari Therapeutics plc
Health Care
Original source

Companies

  • AKTX
    Akari Therapeutics plc
    Health Care

Recent analyst ratings

  • Apr 8UpdateMaxim Group-
  • Jan 5UpdateLadenburg Thalmann$1.00
  • Jul 18UpdateMaxim Group$5.00

Related

  • PR2d
    Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
  • PR3d
    Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
  • SEC13d
    SEC Form POS AM filed by Akari Therapeutics plc
  • PR14d
    Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC
  • ANALYST15d
    Akari Therapeutics downgraded by Maxim Group
  • PR17d
    Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
  • SEC23d
    Amendment: SEC Form F-6/A filed by Akari Therapeutics plc
  • SEC24d
    SEC Form 10-K filed by Akari Therapeutics plc
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022